Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model. [Phase 2]

View source ↗

Summary

Phase 2 study of Mati Therapeutics' olopatadine-PPDS for ragweed-induced seasonal allergic conjunctivitis in an environmental exposure chamber was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seasonal Allergic Conjunctivitis

Drugs mentioned

• Olopatadine-PPDS (olopatadine)

Snippet

Sponsor: Mati Therapeutics Inc. | Conditions: Seasonal Allergic Conjunctivitis to Ragweed | Phase 2 | Status: TERMINATED